Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC
05 Nov 2025
bởiStephen Padilla
An updated analysis of MARIPOSA reveals significant reductions in the incidence of MET and EGFR resistance alterations with first-line amivantamab plus lazertinib compared with osimertinib, with no upregulation in other resistance pathways, in patients with nonsmall cell lung cancer (NSCLC).
Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC
05 Nov 2025
SGLT-2i lowers autoimmune rheumatic disease risk in T2D
04 Nov 2025
bởiStephen Padilla
The use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, compared with sulfonylureas, results in a reduced risk of autoimmune rheumatic disease among adults with type 2 diabetes (T2D), reports a recent study.







